Abu Dhabi and Novartis activate a clinical-trials hub through global Phase 3 programmes
Direct answer
The Department of Health – Abu Dhabi and Novartis announced Phase 3 programme activation across neuroscience, cardiovascular disease, oncology and immunology. The collaboration will support site readiness, study start-up and eligible-patient pathways, while each study and site remains subject to the applicable approvals.
- Editorial author
- Horizon Strategies
- Published
- Last verified in the editorial record
- Scope
- United Arab Emirates · Life Sciences, Clinical Research & Healthcare
Source date: 2026-10-27. This is separate from Horizon publication.
Limits and what this does not prove: Before commitment, verify: Named studies, protocols, participating institutions and site-selection or feasibility milestones; DoH, ethics-committee and institutional approvals for each study and participating site; Published investigator, laboratory, data, recruitment, pharmacovigilance or other service requirements with an accountable contracting route.
Abu Dhabi and Novartis have moved from a two-year collaboration into Phase 3 programme activation, with every study and site still gated by formal feasibility and approvals.
What changed
The Department of Health – Abu Dhabi and Novartis announced Phase 3 programme activation across neuroscience, cardiovascular disease, oncology and immunology. The collaboration will support site readiness, study start-up and eligible-patient pathways, while each study and site remains subject to the applicable approvals.
The Department of Health – Abu Dhabi and Novartis announced activation of the Abu Dhabi Clinical Trials Hub through Novartis global Phase 3 programmes in neuroscience, cardiovascular disease, oncology and immunology. The step follows two years of collaboration after a memorandum signed on 5 June 2024 covering clinical research, evidence generation, healthcare innovation and capability development. The official account does not list the individual protocols, trial phases beyond the stated Phase 3 perimeter, investigators, sites or target enrolment.
The operating agenda is more specific than a general life-sciences ambition. It includes investigator and research-site preparedness, study start-up and initiation, and pathways to identify and refer eligible patients. These functions can create future needs across site operations, laboratories, data, quality, recruitment, logistics and pharmacovigilance, but the source announces no external work package, request for proposal, budget or supplier qualification route.
A research institution or service provider should start with one named protocol and document sponsor, site, investigator, patient and approval responsibilities. The Department and Novartis explicitly state that individual studies and participating sites remain subject to feasibility assessments and regulatory, ethics and institutional approvals. Hub activation therefore should not be recorded as automatic site selection, patient access, clinical demand or a commercial award.
Business impact
- The announced activation covers Novartis global Phase 3 programmes in neuroscience, cardiovascular disease, oncology and immunology.
- Operational work will focus on investigator and site preparedness, study start-up and patient-identification and referral pathways, creating a defined capability-building agenda without naming external supplier demand.
- Research sites and service providers should map their exact role against protocol, feasibility, ethics, regulatory, institutional, data and quality requirements before treating the hub as an addressable opportunity.
Watch next
- Named studies, protocols, participating institutions and site-selection or feasibility milestones
- DoH, ethics-committee and institutional approvals for each study and participating site
- Published investigator, laboratory, data, recruitment, pharmacovigilance or other service requirements with an accountable contracting route
What the evidence supports
- The activation covers global Phase 3 programmes in four named therapeutic areas.
- The programme builds on a DoH–Novartis collaboration dating from June 2024.
- Site readiness, study start-up and eligible-patient pathways are named operating priorities.
- Every study and participating site remains subject to feasibility, regulatory, ethics and institutional approvals.
Horizon interpretation
Why it matters commercially
The announcement strengthens Abu Dhabi’s clinical-research operating base but is not a supplier award or automatic trial placement. Companies need a named protocol, site, approval path, quality requirement and contracting entity before assigning demand.
Questions before acting
- 1Which named protocol, sponsor function and participating institution fit the organisation’s proven capability?
- 2What feasibility, ethics, regulatory, data, quality, staffing and infrastructure evidence must the site provide?
- 3Which written selection or contracting milestone must exist before the organisation allocates staff, equipment or forecast revenue?
Source and editorial position
Therapeutic areas, collaboration history and operating priorities are attributed to DoH Abu Dhabi and Novartis through WAM on 27 October 2026. Horizon preserves the stated feasibility and approval conditions and does not present hub activation as a named trial placement, patient allocation, procurement package or supplier award.
Evidence and decision receipt
What is verified, what remains conditional and what the company can do next
Evidence retained
1
The original Emirates News Agency / Department of Health – Abu Dhabi / Novartis record is retained with its publication date and direct source route.
Decision context
United Arab Emirates · Life Sciences, Clinical Research & Healthcare
Published evidence and Horizon interpretation remain visibly separated.
Unresolved before commitment
Before commitment, verify: Named studies, protocols, participating institutions and site-selection or feasibility milestones; DoH, ethics-committee and institutional approvals for each study and participating site; Published investigator, laboratory, data, recruitment, pharmacovigilance or other service requirements with an accountable contracting route.
Public evidence
Read the integrated analysis, inspect the source route and retain the stated limits.
Review the methodRegistered workspace
Save the item privately, connect it to your company profile and place it on a country or sector watchlist.
Create a free workspaceCommunity decision work
Compare the evidence with full dossiers, mission budgets, Readiness and a company-specific action plan.
Explore Community accessHorizon execution
Request human validation, named-target research, outreach, introductions or market-entry execution.
Explore Horizon supportFound an error or an outdated official route? Use the support channel to request a dated editorial correction; the previous evidence record remains auditable.